Bristol immune drug shows strong effect in melanoma study

By Ben Hirschler MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option. The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer. ...



via Health News Headlines - Yahoo News http://ift.tt/1BufHiX